"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 8 | 10 |
| 1996 | 2 | 16 | 18 |
| 1997 | 4 | 15 | 19 |
| 1998 | 7 | 10 | 17 |
| 1999 | 2 | 21 | 23 |
| 2000 | 7 | 18 | 25 |
| 2001 | 4 | 24 | 28 |
| 2002 | 8 | 41 | 49 |
| 2003 | 10 | 26 | 36 |
| 2004 | 6 | 18 | 24 |
| 2005 | 8 | 16 | 24 |
| 2006 | 6 | 20 | 26 |
| 2007 | 7 | 7 | 14 |
| 2008 | 5 | 14 | 19 |
| 2009 | 7 | 15 | 22 |
| 2010 | 8 | 8 | 16 |
| 2011 | 6 | 10 | 16 |
| 2012 | 4 | 12 | 16 |
| 2013 | 6 | 9 | 15 |
| 2014 | 7 | 5 | 12 |
| 2015 | 6 | 6 | 12 |
| 2016 | 4 | 5 | 9 |
| 2017 | 8 | 1 | 9 |
| 2018 | 9 | 5 | 14 |
| 2019 | 10 | 4 | 14 |
| 2020 | 5 | 5 | 10 |
| 2021 | 9 | 4 | 13 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
Telomerase reverse transcriptase degradation via a rationally designed covalent proteolysis targeting chimera. Bioorg Med Chem Lett. 2025 Sep 01; 125-126:130286.
-
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial. JAMA Neurol. 2025 Apr; 82(4):333-343.
-
Different chemical scaffolds bind to L-phe site in Mycobacterium tuberculosis Phe-tRNA synthetase. Eur J Med Chem. 2025 Apr 05; 287:117335.
-
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
-
Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in? Cancer J. 2023 May-Jun 01; 29(3):188-194.
-
AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis. 2022 08 05; 13(8):678.
-
Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer. J Med Chem. 2021 10 28; 64(20):15280-15296.
-
High-Throughput Enzyme Assay for Screening Inhibitors of the ZDHHC3/7/20 Acyltransferases. ACS Chem Biol. 2021 08 20; 16(8):1318-1324.
-
Development of an Acrylamide-Based Inhibitor of Protein S-Acylation. ACS Chem Biol. 2021 08 20; 16(8):1546-1556.
-
TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. Gastroenterology. 2021 11; 161(5):1475-1486.